performance score. In multivariate analysis, favorable factors for OS were high pretransplant performance status, matched donor/recipient ethnicity, and higher infused colony forming units.
INTRODUCTION
Inherited metabolic disorders (IMD), in particular the lysosomal and peroxisomal storage diseases, cause progressive organ failure and death early in life 1 . In the past 25 years, nearly a thousand patients with these types of storage disorders, including mucopolysaccharidosis (MPS) type I (Hurler syndrome), other MPS, adrenoleukodystrophy (ALD), metachromatic leukodystrophy (MLD), Krabbe disease and others have received allogeneic hematopoietic stem cell transplantation (HSCT) with bone marrow from matched or mis-matched related donors who were either carriers or non-carriers of the disease resulting in clinical benefit in many of them [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] .
The benefit is primarily derived from the replacement of missing enzyme produced by donor cells circulating in the blood and also from engraftment of donor-derived glial cells in the brain [16] [17] [18] [19] . However, many children with IMD who could benefit from HSCT do not have a matched donor. Recent reports demonstrate successful use of banked unrelated donor umbilical cord blood (UCB) transplant (UCBT) for the treatment of malignant and non-malignant diseases [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . Large inventories of UCB units are available in public banks for transplantation in those lacking bone marrow donors.
Due to the rarity of IMD, there has never been a large series of patients transplanted with UCB. We now describe the results of 159 young pediatric patients (92 of whom were previously reported for short term outcomes 22;26;30;31 ) with IMD that were consecutively transplanted with UCB at a single center. This series is unique for several reasons. It represents the first publication describing a larger population of small, young patients, without a malignant diagnosis receiving UCBT after uniform For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From cytoreduction, GvHD prophylaxis and supportive care who were then followed for up to 11 years post transplant. It also allows analysis of the impact of cell dose, HLA matching and graft characteristics, comparing traditional parameters like total nucleated cell dose (TNC) to more complex measurements such as CD34 and CFU, in a population of patients receiving high dose, partially HLA-mismatched UCB grafts where relapse of a malignant disorder was not a competing risk.
METHODS

Patients:
Between August 1995 and April 2007, 159 consecutive young children with IMD referred to Duke University Medical Center were treated with unrelated donor UCBT. These patients lacked HLA-matched, related bone marrow donors who were not carriers of the disease. Diagnoses were confirmed by enzyme or substrate analysis in the peripheral blood or skin fibroblasts 32 . In addition, DNA mutation analyses were performed whenever possible. All patients were enrolled in a Duke University Medical Center IRB approved protocol or treatment plan for transplant. Written informed consent was obtained in all cases according to the Declaration of Helsinki. Sixty-seven of the cases have not been previously reported. Limited and partial data on 92 of 159 patients with a much shorter follow-up has been published previously in the COBLT study 26 and as part of disease specific reports for neonatal Krabbe For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From cells that matched at least 3/6 HLA loci was selected. Molecular matching at HLA-DRB1 was favored and at least one antigen from each locus (A, B, DRB1) was matched.
Units were screened for the genetic disease for which the patient was being transplanted to avoid selection of a carrier donor and the unit with highest enzyme activity was selected whenever possible 33 . Pre-cryopreservation CBU characteristics, including total nucleated cell (TNC) and CD34 content and clonal hematopoietic progenitor cells (colony forming units, CFU), were obtained from the cord blood banks supplying the donor units.
Conditioning Regimen: All patients had central venous catheters placed prior to UCBT.
Patients received myeloablative conditioning with 16 doses of busulfan given orally (n=127) or intravenously (n=32) every 6 hours over 4 days (days -9 to -6) with phenytoin prophylaxis against seizures, followed by cyclophosphamide 50mg/kg/dose for 4 days intravenously with mesna prophylaxis against hemorrhagic cystitis (days -5 to -2), and equine antithymocyte globulin (ATG) 30mg/kg/dose intravenously daily for 3 days (days -3 to -1). Busulfan pharmacokinetics was studied after the first dose, and subsequent doses were adjusted to maintain a steady-state of 600-900 ng/ml. None of the patients received radiation therapy.
Graft Analysis and Transplantation Procedure:
The cryopreserved units of cord blood were thawed and washed as described by Rubinstein et al 34 . The TNC, CD34+ cells, CD3+ cells and CFUs were enumerated; ABO and Rh typing, viability, and bacterial and fungal cultures were performed after thawing. After washing and resuspension in a volume of dextran/albumin solution not to exceed 5cc/kg of the patient's Supportive Care: Patients were nursed in reverse isolation rooms on a dedicated transplant unit with high efficiency particulate air filtration system. Standard prophylaxis against viral pathogens and pneumocystis carinii was used 26;31 . Patients transplanted before 1999 received prophylaxis against fungal infections with low dose amphotericin-B while those transplanted after 2000 received Voriconazole. Empiric broad spectrum antibiotic therapy was started with the first fever. Intravenous immune globulin (500mg/kg/dose) was given weekly until day 100 and then monthly until discontinuation of GvHD therapy and documentation of antibody production. Veno-occlusive disease prophylaxis was continuous infusion heparin (100 units/kg/day) from day -10 to day +28.
Patients received TPN, transfusions of leukocyte-depleted and irradiated packed red cells and platelets, and granulocyte colony stimulating factor 10mcg/kg IV daily from day For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From +1 until their WBC was >5,000/uL. Patients with MPS syndromes underwent tonsillectomy, adenoidectomy and PE tube placement before transplant. MPS patients were also evaluated for increased intracranial pressure by MRI or CT scan and measurement of opening and closing pressures via lumbar puncture prior to initiation of chemotherapy for cytoreduction. If increased intracranial pressure was detected, a ventriculo-peritoneal shunt was placed about 2 weeks before transplant. Patients with feeding problems had G-tubes placed as needed.
Post-Transplantation Evaluation:
Donor cell chimerism and enzyme levels were measured at engraftment, day +100, every 3 months during the first post transplant year and yearly thereafter. Chimerism was confirmed by restriction fragment length polymorphism, microsatellite markers, HLA, or XY fluorescent in-situ hybridization.
Blood enzyme levels were measured when possible (e.g. the enzyme cannot be measured in the blood of patients with Sanfilippo A or ALD). In addition to standard pretransplant organ function studies 31 . The probabilities of neutrophil and platelet engraftment, acute and chronic GvHD were estimated using the cumulative-incidence-function method 37 . Neutrophil engraftment was assessed in patients surviving to day 14 treating death without the event as a competing risk while autologous reconstitution was censored. For platelet engraftment, acute and chronic GvHD, patients were evaluable after surviving to Day 14 and death without the event was the competing event while patients were censored on the last day of follow-up. Differences between subgroups were compared using Grays K-Sample Test
38
. The probability of overall survival was calculated with the use of the Kaplan-Meier estimator 39 and differences between groups were compared using the log-rank statistics 40 . seropositive, a lower rate than seen in previously reported patient cohorts, likely due to the younger age of these patients, A large proportion of patients (41.5%) had a poor performance status (Lansky <80%). The median time between the initial patient evaluation at our center and start of cytoreduction was 34.5 days while the median time between the date of diagnosis and start of cytoreduction was 87 days. All but 7 patients received grafts mismatched at 1 (n=75), 2 (n=73) or 3 (n=4) HLA loci. Eighty-eight (55%) donor/graft pairs were matched for ABO, 81 (50.9%) were matched for sex and 123 (82%) were matched for ethnicity.
Characteristics of the cord blood grafts:
The median TNC/kg of the selected grafts (pre-cryopreservation) was 9.73x10 7 cells/kg (range 2.24-50.37) using data provided by the cord blood banks. The median doses infused from the thawed graft (measured in (Table 2B) . (Table 2C) .
Graft versus host disease:
Seven patients developed isolated autoimmune hemolytic anemia and/or cytopenia without other features of cGvHD.
Overall survival and causes of death:
The estimated probability of overall survival Figure 1D ). In univariate analysis, performance status of 80-100
by Lansky (P<0.0001) and a higher CFU infused (p<0.01) were significantly associated with a higher probability of OS. In multivariate analysis, performance status ( Figure 1F ) respectively. Kaplan-Meir estimates of probability of overall survival for various diagnoses were determined and are presented in Figure 3 . The 1 year probability of overall survival (depicted within the parentheses after each disease) for Krabbe Disease Clinical outcomes and follow-up: All engrafting patients, except 3, achieved donor chimerism of >90%. All but 4 engrafting patients with diseases for which leukocyte or plasma enzyme level measurements exist achieved and sustained normal enzyme One patient with Pelizaeus Merzbacher Disease was transplanted at 9 months of age.
He is now 2.5 years old and has experienced continued but slow functional gains in both cognitive and motor skills. Nerve conduction studies, which were abnormal pretransplant, have normalized. MRI shows progressive improvement in myelination.
Nystagmus, involuntary movements and ataxia have improved but not resolved. Vision and hearing are normal.
DISCUSSION:
We describe outcomes of a large series of predominantly small and young children with IMD belonging to the lysosomal and peroxisomal disorders transplanted with UCBT at a single center after uniform cytoreduction and followed for 1-11 years (median 4.6 years).
Important variables influencing overall survival included better performance status (p=<0.0001), higher CFU infused (p=0.02) and matched ethnicity between the CBU and the recipient (p=0.05). The cumulative incidence (87.1% by Day 42) and speed (median of day +22) of neutrophil engraftment was higher and faster than previously reported in large cohort studies 27;28;42 . The majority of patients (97%) achieved and sustained full donor chimerism (>90%) and normalized enzyme levels where measurable. This high level of donor chimerism is better than those reported in the literature following unrelated bone marrow transplantation. While detailed, disease specific outcomes are not fully described in this report, all surviving children with good performance status at /kg, respectively) than those of varied age and size previously reported.
Platelet engraftment was also accelerated, likely related to higher cell dosing.
An analysis of the impact of HLA matching on GvHD and survival could be studied in this group of patients who, because of their diagnosis did not have relapse as a competing risk , and who also received very high cell doses from a single UCB graft. In this context, HLA matching approached significance (p=0.07) as a predictor of overall survival although it did not influence the incidence or severity of acute or chronic GvHD.
It should be noted that the sample size in this series may be too small to fully appreciate the impact of HLA matching. This notion is supported by the observation that ethnic disparity between the donor and recipient was a significant predictor of chronic GvHD (p=0.002) and overall survival (p=0.05) as ethnicity may be a surrogate marker for HLA matching. Further analysis of the impact of HLA matching should continue to be examined both by analyses of high resolution matching and inclusion of other HLA loci (e.g. HLA C) in larger series of patients, perhaps through registry analyses.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From Of interest are the observations that donor/recipient gender may influence UCB transplant outcomes. In multivariate analyses in this patient cohort, neutrophil engraftment was higher in male patients and platelet engraftment was higher in patients transplanted with a female donor. It is also noteworthy that in multivariate analysis, boys had a better survival in the pediatric malignancy stratum of the COBLT trial.
These observations may be clinically important although not proven in these smaller cohorts. One might speculate that disparities of the H-Y minor histocompatibility antigens may be responsible for these results. This hypothesis will have to be tested in a much larger series of patients to be accepted as valid.
The previously unreported observation that infused (post thaw) CFU is the graft characteristic that best correlated with engraftment of both neutrophils and platelets as well as overall survival in multivariate analysis is very important. The fact that TNC, viability, CD34 and CFUs were enumerated on all thawed CBUs in the same laboratory using standard SOPs, allowed these observations to emerge. Given the need for development of potency and release assay for cord blood, our data would suggest that post thaw CFU could serve this purpose. Standardization and validation of the assay between cord blood banks and transplant center laboratories would be required.
Studies looking at correlations between CFUs recovered from a thawed segment and
CFUs from the bag are underway in our laboratory and by others, to determine whether former could be used as a product release assay in the future.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From ABO mismatching was a significant predictor of both acute and chronic GvHD (p=<0.01). This patient cohort also had a relatively higher incidence of autoimmune cytopenias, particularly in younger patients. We have seen high incidence of autoimmune cytopenia and hemolytic anemia in infants and young children undergoing UCBT 43 . The mechanisms underlying the impact of ABO matching on these manifestations of GVHD is unclear but should be the subject of future and larger studies. Most of the patients developed autoimmune hematological problems during or after the tapering of immunosuppression (later in the course of transplant). Alterations in thymic ontogeny by both cytoreduction and post-transplant immunosuppressive therapy may explain the higher incidence of autoimmune problems in this younger patient cohort.
In the last 25 years, about 1000 HSCT for inherited metabolic disorders have been Table 5 compares the outcome data from current series with those previously published for BMT for Hurler and ALD. The rates of engraftment and overall survival at 2 years in a group of 40 Hurler syndrome patients transplanted from unrelated bone marrow donors at 14 different centers were 62.5% and 49% respectively 5 . Of the survivors, approximately 30% had no donor cell engraftment. A retrospective analysis of 74 transplants for Hurler syndrome from URD BM or PBSC performed at 16 centers revealed an "alive and engrafted" rate of <55% at 3.7 years follow-up but a higher engraftment rate for UCBT patients. In a retrospective questionnaire-based analysis of 94 patients with ALD at 43 centers, of whom 52 received unrelated donor (83% bone marrow) transplantation, For personal use only. on November 12, 2017. by guest www.bloodjournal.org From the probability of overall survival following unrelated donor transplant was 53% 7;45 . In another study of haploidentical bone marrow transplant for Hurler disease only 9 of 26 (35%) were engrafted and alive at a median follow-up of 4.6 years. In comparison, the probabilities of donor cell engraftment at 42 days and overall survival at 1, 3, and 5 years post-transplant in our group of patients who underwent unrelated UCBT were 87.1%, 79.0%, 71.8%, and 58.2%, respectively. In patients with high performance status (80-100), the overall survival at 1, 3 and 5 years was 84.5%, 77.9%, and 75.7%, respectively. Outcome data on a large series of patients transplanted at a single center with consistent cytoreduction and supportive care may reflect expertise in treating larger numbers of patients with these rare diagnoses. However, there may also be patient selection and referral pattern bias.
Published and current data confirm that HSCT, including UCBT are effective in the treatment for some inherited metabolic diseases. However, the procedure carries significant risks due to the effects of preparative regimens and donor-host immunological interactions. The late effects of administration of chemotherapy at an early age and the "natural history" of these diseases in transplanted patients are not known at the present time. Development of strategies to reduce early and late toxicities of transplantation therapy including the use of reduced intensity cytoreduction without compromising engraftment may decrease morbidity and mortality in the future. (Table 2C) . Table 3 -Result of univariate and multivariate analyses of graft and patient factors on overall survival (OS). Table 4 -Causes of death in patients: grouped according to the high (Lansky 80-100) and low (Lansky <80) performance status at the time of transplantation. 
